https://www.biopharmawatch.com/news/SGHT/sight-sciences-fda-clearance-omni-ultra-surgical-system BiopharmaWatch en 2026-08-04T21:37:00.000Z Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q2-2026-update BiopharmaWatch en 2026-08-04T21:06:00.000Z CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-04T20:30:00.000Z DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 https://www.biopharmawatch.com/news/PACS/pacs-group-inc-reports-q2-2026-results BiopharmaWatch en 2026-08-04T20:30:00.000Z PACS Group, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T20:30:00.000Z Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-fy2026-financial-results BiopharmaWatch en 2026-08-04T20:30:00.000Z JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-q2-2026-results BiopharmaWatch en 2026-08-04T20:15:00.000Z Ardent Health Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-patrick-ellinor-board BiopharmaWatch en 2026-08-04T20:15:00.000Z Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. https://www.biopharmawatch.com/news/BIO/bio-rad-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:15:00.000Z Bio-Rad Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EHTH/ehealth-announces-q2-2026-results BiopharmaWatch en 2026-08-04T20:15:00.000Z eHealth, Inc. Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IQV/iqvia-medera-collaboration-cardiac-gene-therapy BiopharmaWatch en 2026-08-04T20:15:00.000Z IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z ATEC Reports Second Quarter Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-appoints-warren-foust-ceo BiopharmaWatch en 2026-08-04T20:05:00.000Z STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer https://www.biopharmawatch.com/news/HNGE/hinge-health-q2-2026-results-acquisition-cylinder-health BiopharmaWatch en 2026-08-04T20:05:00.000Z Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health https://www.biopharmawatch.com/news/USNA/usana-health-sciences-q2-2026-results BiopharmaWatch en 2026-08-04T20:05:00.000Z USANA Health Sciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/JNJ/johnson-johnson-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-04T20:05:00.000Z Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/HNGE/hinge-health-acquires-cylinder-health-gastrointestinal-care BiopharmaWatch en 2026-08-04T20:05:00.000Z Hinge Health to acquire Cylinder Health, expanding into gastrointestinal care https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-04T20:05:00.000Z Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XTNT/xtant-medical-participate-canaccord-growth-conference BiopharmaWatch en 2026-08-04T20:05:00.000Z Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/INO/inovio-report-second-quarter-financial-results-2026 BiopharmaWatch en 2026-08-04T20:05:00.000Z INOVIO to Report Second Quarter Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/TMDX/transmedics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z TransMedics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-q2-2026-results-highlights BiopharmaWatch en 2026-08-04T20:05:00.000Z Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-04T20:05:00.000Z Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q2-2026-financial-results-webcast BiopharmaWatch en 2026-08-04T20:05:00.000Z LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 https://www.biopharmawatch.com/news/IRIX/iridex-q2-2026-financial-results-report BiopharmaWatch en 2026-08-04T20:05:00.000Z Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026 https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z LeMaitre Q2 2026 Financial Results https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:02:00.000Z Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T20:02:00.000Z Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RIGL/rigel-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Rigel Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-q2-2026-earnings-call BiopharmaWatch en 2026-08-04T20:01:00.000Z STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026 https://www.biopharmawatch.com/news/PSNL/personalis-reports-q2-results-highlights BiopharmaWatch en 2026-08-04T20:01:00.000Z Personalis Reports Second Quarter Results and Recent Highlights https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Travere Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TWST/twist-bioscience-public-offering-250-million BiopharmaWatch en 2026-08-04T20:01:00.000Z Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-fiscal-2026-q3-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results https://www.biopharmawatch.com/news/GILD/gilead-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Gilead Sciences Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/PGEN/precigen-q2-2026-financial-results-papzimeos-growth BiopharmaWatch en 2026-08-04T20:01:00.000Z Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T20:01:00.000Z Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q2-2026-results-announcement BiopharmaWatch en 2026-08-04T20:01:00.000Z Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Pacira BioSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-acquires-fda-priority-review-voucher BiopharmaWatch en 2026-08-04T20:00:00.000Z Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q2-2026-results-webcast BiopharmaWatch en 2026-08-04T20:00:00.000Z Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 https://www.biopharmawatch.com/news/PNTG/pennant-acquires-river-centre-assisted-living-tucson BiopharmaWatch en 2026-08-04T20:00:00.000Z Pennant Acquires River Centre Assisted Living in Tucson, Arizona https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-brainstorm-collaboration-parkinsons-data-readout BiopharmaWatch en 2026-08-04T19:28:00.000Z Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 https://www.biopharmawatch.com/news/NVO/novo-nordisk-q2-2026-profit-outlook BiopharmaWatch en 2026-08-04T16:37:00.000Z Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook https://www.biopharmawatch.com/news/NVO/novo-nordisk-sales-profit-outlook-2026 BiopharmaWatch en 2026-08-04T16:33:00.000Z Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q2-2026-conference-call BiopharmaWatch en 2026-08-04T16:25:02.000Z August 12, 2026 5:00 PM EDT : The Allogene Therapeutics Second Quarter 2026 Conference Call https://www.biopharmawatch.com/news/PCVX/intellectual-fitness-suggestions-mental-health BiopharmaWatch en 2026-08-04T15:25:57.000Z Intellectual Fitness Suggestions to Show Your brain and you may Increase Better-Becoming https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-names-defendants-naked-short-selling-suit BiopharmaWatch en 2026-08-04T13:20:00.000Z Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-preclinical-findings BiopharmaWatch en 2026-08-04T13:15:00.000Z Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers https://www.biopharmawatch.com/news/IMMX/immix-biopharma-morgan-stanley-conference-2026 BiopharmaWatch en 2026-08-04T13:15:00.000Z Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CVS/cvs-health-stevie-awards-ai-learning-academy BiopharmaWatch en 2026-08-04T13:00:00.000Z CVS Health earns two Gold and one Silver Stevie® Awards for Great Employers https://www.biopharmawatch.com/news/NVO/h1-partners-novo-nordisk-ai-clinical-development BiopharmaWatch en 2026-08-04T13:00:00.000Z H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development https://www.biopharmawatch.com/news/FEED/envue-medical-nanovibronix-manufacturing-us BiopharmaWatch en 2026-08-04T13:00:00.000Z ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-strategic-whitehawk-collaboration BiopharmaWatch en 2026-08-04T12:50:00.000Z Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation https://www.biopharmawatch.com/news/JNJ/j-j-executive-vice-president-jennifer-taubert-retire BiopharmaWatch en 2026-08-04T12:45:00.000Z Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September https://www.biopharmawatch.com/news/VERU/veru-patent-enobosarm-semaglutide-weight-loss BiopharmaWatch en 2026-08-04T12:30:00.000Z Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss https://www.biopharmawatch.com/news/EOLS/evolus-expands-partnership-symatese-estyme-canada-australia-new-zealand BiopharmaWatch en 2026-08-04T12:30:00.000Z Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand https://www.biopharmawatch.com/news/QTI/qt-imaging-advances-us-commercial-strategy-breast-ct-scanner BiopharmaWatch en 2026-08-04T12:30:00.000Z QT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires https://www.biopharmawatch.com/news/BAX/baxter-announces-cash-tender-offers BiopharmaWatch en 2026-08-04T12:30:00.000Z Baxter Announces Cash Tender Offers https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-canyon-1-study-crb-913-obesity BiopharmaWatch en 2026-08-04T12:30:00.000Z Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity https://www.biopharmawatch.com/news/RNXT/renovorx-highlight-tamp-platform-webinar-pancreatic-cancer BiopharmaWatch en 2026-08-04T12:30:00.000Z RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th https://www.biopharmawatch.com/news/MLSS/milestone-scientific-red-one-medical-partnership BiopharmaWatch en 2026-08-04T12:30:00.000Z Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-2-data-eb613-asbmr-2026 BiopharmaWatch en 2026-08-04T12:30:00.000Z Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-04T12:30:00.000Z Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:30:00.000Z Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update https://www.biopharmawatch.com/news/AMIX/autonomix-medical-expands-precision-neuromodulation-platform BiopharmaWatch en 2026-08-04T12:15:00.000Z Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy https://www.biopharmawatch.com/news/XAIR/beyond-air-conference-call-financial-results-august-2026 BiopharmaWatch en 2026-08-04T12:09:57.906Z Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/TFX/teleflex-medical-oem-launches-ingenyx BiopharmaWatch en 2026-08-04T12:09:40.695Z Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators https://www.biopharmawatch.com/news/RANI/rani-therapeutics-appoints-michelle-gilson-board BiopharmaWatch en 2026-08-04T12:00:21.000Z Rani Therapeutics Appoints Michelle Gilson to Board of Directors https://www.biopharmawatch.com/news/ABBV/fda-acceptance-botox-masseter-muscle-prominence BiopharmaWatch en 2026-08-04T12:00:00.000Z Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence https://www.biopharmawatch.com/news/ENGN/engene-virtual-kol-event-nmibc-insights-august-2026 BiopharmaWatch en 2026-08-04T12:00:00.000Z enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 https://www.biopharmawatch.com/news/QTRX/quanterix-report-second-quarter-2026-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/CVM/celsci-multikine-biomarker-strategy-study BiopharmaWatch en 2026-08-04T12:00:00.000Z CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study https://www.biopharmawatch.com/news/TWST/twist-bioscience-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T12:00:00.000Z Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NUVB/nuvation-bio-ibtrozi-pivotal-data-wclc-esmo BiopharmaWatch en 2026-08-04T12:00:00.000Z Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-funding-agreement-ault-lending BiopharmaWatch en 2026-08-04T12:00:00.000Z Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T12:00:00.000Z Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/IMNN/imunon-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-08-04T12:00:00.000Z IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-clinical-data-publication BiopharmaWatch en 2026-08-04T12:00:00.000Z Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications https://www.biopharmawatch.com/news/XGN/exagen-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Exagen Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q2-2026-financial-results-highlights BiopharmaWatch en 2026-08-04T12:00:00.000Z Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-debt-equity-conversion BiopharmaWatch en 2026-08-04T12:00:00.000Z Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/ABEO/cms-grants-ntap-status-for-zevaskyn BiopharmaWatch en 2026-08-04T11:30:00.000Z CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN® https://www.biopharmawatch.com/news/IBRX/immunitybio-record-q2-2026-revenue BiopharmaWatch en 2026-08-04T11:30:00.000Z ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:30:00.000Z Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q2-2026-revenue-bp-205-data BiopharmaWatch en 2026-08-04T11:30:00.000Z Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T11:30:00.000Z Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-08-04T11:30:00.000Z Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-second-closing-private-placement BiopharmaWatch en 2026-08-04T11:20:16.747Z CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement https://www.biopharmawatch.com/news/ACON/aclarion-nociscan-goodman-campbell-indiana BiopharmaWatch en 2026-08-04T11:14:39.464Z Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-08-04T11:14:25.015Z Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/NRXS/neuraxis-expands-payer-coverage-ib-stim BiopharmaWatch en 2026-08-04T11:14:02.683Z NeurAxis Expands Payer Coverage with New Policies https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:01:00.000Z Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T11:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-q2-2026-results-beam-302-trial BiopharmaWatch en 2026-08-04T11:00:30.000Z Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) https://www.biopharmawatch.com/news/IBIO/ibio-appoints-molly-carr-cmo-strengthens-leadership BiopharmaWatch en 2026-08-04T11:00:00.000Z iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer https://www.biopharmawatch.com/news/AHCO/adapthealth-q2-2026-results BiopharmaWatch en 2026-08-04T11:00:00.000Z AdaptHealth Corp. Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/BRKR/bruker-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:00:00.000Z Bruker Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMDX/imdx-second-quarter-results-august-2026 BiopharmaWatch en 2026-08-04T11:00:00.000Z iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-dnth312-bifunctional-fusion-protein BiopharmaWatch en 2026-08-04T11:00:00.000Z Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T11:00:00.000Z Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ARVN/arvinas-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:00:00.000Z Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-heather-getz-ceo BiopharmaWatch en 2026-08-04T11:00:00.000Z TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-update-merger-termination BiopharmaWatch en 2026-08-04T11:00:00.000Z Lisata Therapeutics Provides Update Following Termination of Merger Agreement https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-04T11:00:00.000Z Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update https://www.biopharmawatch.com/news/LH/labcorp-launches-fda-approved-pten-companion-diagnostic BiopharmaWatch en 2026-08-04T11:00:00.000Z Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-rm-718-phase-2-trial-results BiopharmaWatch en 2026-08-04T10:55:00.000Z Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity https://www.biopharmawatch.com/news/PFE/pfizer-reports-q2-results-raises-revenue-guidance BiopharmaWatch en 2026-08-04T10:45:00.000Z Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance https://www.biopharmawatch.com/news/BNTX/biontech-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T10:45:00.000Z BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/STVN/stevanato-group-revenue-growth-q2-fiscal-2026 BiopharmaWatch en 2026-08-04T10:30:00.000Z Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 https://www.biopharmawatch.com/news/MRK/merck-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-04T10:30:00.000Z Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T10:30:00.000Z InfuSystem Announces Financial Results for Second Quarter 2026 https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T10:00:00.000Z Revvity Announces Financial Results for the Second Quarter of 2026 https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-q2-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Pediatrix Medical Group Reports Second Quarter Results https://www.biopharmawatch.com/news/HSIC/henry-schein-q2-2026-financial-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance https://www.biopharmawatch.com/news/WAT/waters-corporation-q2-2026-financial-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T10:00:00.000Z IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BDSX/biodesix-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-08-04T10:00:00.000Z Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-innovation-passport-dlb BiopharmaWatch en 2026-08-04T09:15:00.000Z CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) https://www.biopharmawatch.com/news/VTGN/srx-global-acquires-stake-vistagen-therapeutics BiopharmaWatch en 2026-08-04T09:00:00.000Z SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) https://www.biopharmawatch.com/news/PHAR/pharming-participate-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-04T06:00:00.000Z Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PCVX/digital-platforms-enhancing-collaboration-pcvx BiopharmaWatch en 2026-08-04T05:54:21.000Z Ведущие платформы для коллективной деятельности над задачами https://www.biopharmawatch.com/news/PCVX/optimal-solutions-for-group-activities BiopharmaWatch en 2026-08-04T05:45:36.000Z Оптимальные решения для групповой деятельности над задачами https://www.biopharmawatch.com/news/PCVX/online-education-accelerated-pandemic BiopharmaWatch en 2026-08-04T05:09:18.000Z Почему онлайн-обучение превратилось свежей правилом https://www.biopharmawatch.com/news/SNY/sanofi-menquadfi-eu-approval-infants-meningococcal-disease BiopharmaWatch en 2026-08-04T05:00:00.000Z Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease https://www.biopharmawatch.com/news/NRIX/nurix-phase-3-daybreak-cll-306-trial-bexobrutideg BiopharmaWatch en 2026-08-04T05:00:00.000Z Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma https://www.biopharmawatch.com/news/PCVX/top-portable-services-for-students BiopharmaWatch en 2026-08-04T04:26:20.000Z Топовые портативные сервисы для учащихся https://www.biopharmawatch.com/news/YDES/yd-bio-peer-reviewed-publication-computational-framework BiopharmaWatch en 2026-08-04T04:17:34.000Z YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research https://www.biopharmawatch.com/news/YDES/yd-bio-tmu-collaboration-corneal-research BiopharmaWatch en 2026-08-04T04:17:32.000Z YD Bio 發表圓錐角膜研究新成果，與台北醫學大學攜手建立再生療法科學基礎 https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T22:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) https://www.biopharmawatch.com/news/APMD/apnimed-upsized-ipo-2026 BiopharmaWatch en 2026-08-03T20:35:00.000Z Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T20:30:00.000Z Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HSTM/healthstream-announces-second-quarter-2026-results BiopharmaWatch en 2026-08-03T20:30:00.000Z HealthStream Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-mark-anquillare-board BiopharmaWatch en 2026-08-03T20:30:00.000Z Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors https://www.biopharmawatch.com/news/CV/capso-vision-launch-ai-highlights BiopharmaWatch en 2026-08-03T20:30:00.000Z CapsoVision® Announces International Launch of AI Highlights https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-record-q2-results BiopharmaWatch en 2026-08-03T20:15:00.000Z UFP Technologies Announces Record Q2 Results https://www.biopharmawatch.com/news/TFX/teleflex-divestiture-oem-business-1-5-billion BiopharmaWatch en 2026-08-03T20:15:00.000Z Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion https://www.biopharmawatch.com/news/HAE/vascade-mvp-xl-effectiveness-electrophysiology-procedures BiopharmaWatch en 2026-08-03T20:15:00.000Z New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths https://www.biopharmawatch.com/news/AEON/aeon-biopharma-regains-compliance-nyse-american BiopharmaWatch en 2026-08-03T20:15:00.000Z AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q2-2026 BiopharmaWatch en 2026-08-03T20:15:00.000Z CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SEER/seer-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-08-03T20:15:00.000Z Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q2-2026-results-and-guidance BiopharmaWatch en 2026-08-03T20:09:00.000Z SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance https://www.biopharmawatch.com/news/ADUS/addus-homecare-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Addus HomeCare Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/WGS/genedx-reports-q2-2026-results BiopharmaWatch en 2026-08-03T20:05:00.000Z GeneDx Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HIT/health-in-tech-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-03T20:05:00.000Z Health In Tech to Announce Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/SEER/seer-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LGVN/longeveron-report-2026-q2-results-conference-call BiopharmaWatch en 2026-08-03T20:05:00.000Z Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 https://www.biopharmawatch.com/news/GUTS/fractyl-health-q2-2026-financial-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q2-2026-results BiopharmaWatch en 2026-08-03T20:02:00.000Z Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan https://www.biopharmawatch.com/news/VRTX/vertex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Vertex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-q2-2026-results-updates BiopharmaWatch en 2026-08-03T20:01:00.000Z Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Keros Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-september-2026 BiopharmaWatch en 2026-08-03T20:01:00.000Z argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:00:00.000Z ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 https://www.biopharmawatch.com/news/HQY/healthequity-second-quarter-earnings-release BiopharmaWatch en 2026-08-03T20:00:00.000Z HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule https://www.biopharmawatch.com/news/HCSG/community-health-center-services-explained BiopharmaWatch en 2026-08-03T19:11:00.000Z In HelloNation, Healthcare Services Expert Sheila A. Berschauer Explains What a Community Health Center Can Help With https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-income-growth-q2-2026 BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-appoints-cassie-mclean-ceo-care-delivery BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery https://www.biopharmawatch.com/news/XCUR/exicure-settle-gpcr-therapeutics-milestone-payment BiopharmaWatch en 2026-08-03T13:24:00.000Z Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance https://www.biopharmawatch.com/news/REVB/gemini-market-assessment-acute-kidney-injury BiopharmaWatch en 2026-08-03T13:00:00.000Z Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T13:00:00.000Z Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-expands-ip-portfolio-antivirals BiopharmaWatch en 2026-08-03T13:00:00.000Z Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform https://www.biopharmawatch.com/news/SBC/sbc-medical-2q-2026-financial-results-announcement BiopharmaWatch en 2026-08-03T13:00:00.000Z SBC Medical to Announce 2Q 2026 Financial Results https://www.biopharmawatch.com/news/AIM/aim-immunotech-last-dose-duripanc-clinical-trial BiopharmaWatch en 2026-08-03T12:33:00.000Z AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-evotec-nb4168-preclinical-development BiopharmaWatch en 2026-08-03T12:32:00.000Z Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-report-q2-2026-results BiopharmaWatch en 2026-08-03T12:30:00.000Z Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update https://www.biopharmawatch.com/news/OMER/cms-grants-ntap-status-yartemlea BiopharmaWatch en 2026-08-03T12:30:00.000Z CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® https://www.biopharmawatch.com/news/ADGM/adagio-medical-first-patient-ulta-system BiopharmaWatch en 2026-08-03T12:30:00.000Z Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-new-leaders-cmc-supply-chain-quality BiopharmaWatch en 2026-08-03T12:30:00.000Z Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-interference-study-fingerprinting BiopharmaWatch en 2026-08-03T12:30:00.000Z Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-james-ahlers-cfo-ind-submission BiopharmaWatch en 2026-08-03T12:30:00.000Z Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-cad-1005-strategy-update BiopharmaWatch en 2026-08-03T12:30:00.000Z Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation https://www.biopharmawatch.com/news/VERU/veru-report-fiscal-2026-third-quarter-results BiopharmaWatch en 2026-08-03T12:30:00.000Z Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-astro-2026 BiopharmaWatch en 2026-08-03T12:05:00.000Z Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 https://www.biopharmawatch.com/news/CMND/clearmind-acquires-majority-stake-ev-wireless-charging BiopharmaWatch en 2026-08-03T12:02:00.000Z Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company https://www.biopharmawatch.com/news/TSHA/taysha-catalent-partnership-tsha-102-rett-syndrome BiopharmaWatch en 2026-08-03T12:00:13.000Z Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q2-2026-earnings-release BiopharmaWatch en 2026-08-03T12:00:00.000Z Sonida Senior Living Announces Second Quarter Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-jessica-cohen-pfeffer BiopharmaWatch en 2026-08-03T12:00:00.000Z Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-oregon-health-science-university BiopharmaWatch en 2026-08-03T12:00:00.000Z Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/ACXP/fda-guidance-acurx-ibezapolstat-phase-3-trial BiopharmaWatch en 2026-08-03T12:00:00.000Z FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-chief-legal-officer BiopharmaWatch en 2026-08-03T12:00:00.000Z CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer https://www.biopharmawatch.com/news/AKBA/akebia-phase-2-trial-ebribafusp-kidney-diseases BiopharmaWatch en 2026-08-03T12:00:00.000Z Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases https://www.biopharmawatch.com/news/DSGN/design-therapeutics-restore-fa-update-q2-2026-results BiopharmaWatch en 2026-08-03T12:00:00.000Z Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALT/altimmune-performa-phase-3-trial-pemvidutide-mash BiopharmaWatch en 2026-08-03T12:00:00.000Z Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH https://www.biopharmawatch.com/news/AVXL/anavex-refresh-board-stockholder-value-creation BiopharmaWatch en 2026-08-03T12:00:00.000Z Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation https://www.biopharmawatch.com/news/STIM/neuronetics-chernett-shared-vision BiopharmaWatch en 2026-08-03T12:00:00.000Z Neuronetics and Jorey Chernett Announce Shared Vision https://www.biopharmawatch.com/news/CARL/carlsmed-favorable-reimbursement-aprevo-lumbar BiopharmaWatch en 2026-08-03T12:00:00.000Z Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-03T12:00:00.000Z Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/LPCN/lipocine-appoints-michael-grissinger-board-directors BiopharmaWatch en 2026-08-03T12:00:00.000Z Lipocine Appoints Michael J. Grissinger to Board of Directors https://www.biopharmawatch.com/news/LLY/lilly-olomorasib-fda-breakthrough-therapy-designation BiopharmaWatch en 2026-08-03T11:45:00.000Z Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer https://www.biopharmawatch.com/news/LNTH/curium-lantheus-merger-agreement BiopharmaWatch en 2026-08-03T11:38:00.000Z Curium Announces Definitive Agreement to Merge with Lantheus https://www.biopharmawatch.com/news/LTRN/lantern-pharma-open-medicine-ai-launch BiopharmaWatch en 2026-08-03T11:30:00.000Z Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine https://www.biopharmawatch.com/news/BBIO/bridgebio-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-03T11:30:00.000Z BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-arimoclomol-npc-real-world-data BiopharmaWatch en 2026-08-03T11:30:00.000Z Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) https://www.biopharmawatch.com/news/MDCX/medicus-pharma-appoints-dr-faisal-mehmud-ceo-antev-limited BiopharmaWatch en 2026-08-03T11:30:00.000Z Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-august-2026 BiopharmaWatch en 2026-08-03T11:30:00.000Z ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-q3-results BiopharmaWatch en 2026-08-03T11:15:00.000Z Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-august-2026 BiopharmaWatch en 2026-08-03T11:05:00.000Z REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/CANF/can-fite-clinical-program-piclidenoson-lowe-syndrome BiopharmaWatch en 2026-08-03T11:00:00.000Z Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-positive-safety-update-rp-a501 BiopharmaWatch en 2026-08-03T11:00:00.000Z Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease https://www.biopharmawatch.com/news/ZLAB/fda-orphan-drug-designation-zai-lab-zoci BiopharmaWatch en 2026-08-03T11:00:00.000Z U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/CGEN/compugen-reports-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Compugen Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/GNPX/genprex-collaboration-roche-biomarker-assay-validation BiopharmaWatch en 2026-08-03T11:00:00.000Z Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-q2-2026-financial-results-briumvi-guidance BiopharmaWatch en 2026-08-03T11:00:00.000Z TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-3-trial-opgx-lca5-enrollment-complete BiopharmaWatch en 2026-08-03T11:00:00.000Z Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-4800-fda-meeting BiopharmaWatch en 2026-08-03T11:00:00.000Z Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q2-2026-financial-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ANL/adlai-nortye-phase-i-trial-an4035-australia BiopharmaWatch en 2026-08-03T11:00:00.000Z Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia https://www.biopharmawatch.com/news/CBLL/ceribell-cms-ntap-delirium-monitor BiopharmaWatch en 2026-08-03T11:00:00.000Z Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-opko-health-investment-norovirus-data BiopharmaWatch en 2026-08-03T11:00:00.000Z Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T10:50:00.000Z Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/SUPN/supernus-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-03T10:35:00.000Z Supernus Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DRIO/dariohealth-q2-2026-results-conference-call BiopharmaWatch en 2026-08-03T10:30:00.000Z DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/SUPN/supernus-indivior-merger-cns-biopharmaceutical-leader BiopharmaWatch en 2026-08-03T10:30:00.000Z Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale https://www.biopharmawatch.com/news/PCVX/online-education-transformation-pandemic BiopharmaWatch en 2026-08-03T10:08:58.000Z Почему онлайн-обучение превратилось новой нормой https://www.biopharmawatch.com/news/BNTX/biontech-appoints-dr-guido-oelkers-ceo BiopharmaWatch en 2026-08-03T09:00:00.000Z BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden https://www.biopharmawatch.com/news/BNTX/biontech-appoints-guido-oelkers-ceo BiopharmaWatch en 2026-08-03T09:00:00.000Z BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer https://www.biopharmawatch.com/news/OCS/oculis-positive-fda-feedback-privosegtor-ms-relapses BiopharmaWatch en 2026-08-03T08:00:00.000Z Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-03 BiopharmaWatch en 2026-08-03T07:17:36.944Z Biotech Catalysts to Watch: Key Developments for August 2026 https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-08-03T07:16:57.252Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-08-03T07:16:15.359Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-august-2026 BiopharmaWatch en 2026-08-03T07:15:41.154Z FDA Calendar August 2026: Key PDUFA Dates and Analysis https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T00:00:00.000Z Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026....